The Food and Drug Administration has approved the first seasonal flu vaccine in the United States built on messenger RNA technology, clearing it for adults 50 and older roughly two months before the 2026–2027 respiratory virus season typically begins. The shot, called mFLUSIVA, received full approval for adults 50 to 64 and accelerated approval for adults 65 and older, with the manufacturer required to complete an additional confirmatory trial in the older group.
For households, the practical question is simple: adults turning 50 or caring for an aging parent now have another option on the shelf when pharmacies begin fall flu clinics. Moderna says the vaccine will be available within a few weeks, according to NPR's report on the approval. It does not replace existing flu shots, and it is not authorized for anyone under 50.
